臨床泌尿器科76巻8号

2022年07月発行

特集 泌尿器腫瘍における放射線治療―変革期を迎えた令和のトレンド

〈前立腺癌〉

オリゴ転移前立腺癌に対するmetastasis-directed therapy

著者： 吉田宗一郎¹ 藤井靖久¹

所属機関： ¹東京医科歯科大学大学院医歯学総合研究科腎泌尿器外科学教室

ページ範囲：P.546 - P.552

文献概要

▶ポイント

・オリゴ転移癌は，限局癌と多発転移癌の中間的な状態であると考えられている．

・オリゴ転移前立腺癌に対して，去勢抵抗性前立腺癌を含め，転移病変に対する標的治療が検討されるようになっている．

・オリゴ転移癌の分類についての検討が進んでおり，オリゴ転移前立腺癌に対する治療アプローチの最適化に期待される．

参考文献

1） Hellman S, et al : Oligometastases. J Clin Oncol 13 : 8-10, 1995

2） Yang L, et al : Evaluation of the 7 （th） and 8 （th） Editions of the AJCC/UICC TNM Staging Systems for Lung Cancer in a Large North American Cohort. Oncotarget 8 : 66784-66795, 2017

3） Salama JK, et al : Stereotactic Body Radiotherapy for Multisite Extracranial Oligometastases : Final Report of a Dose Escalation Trial in Patients with 1 to 5 Sites of Metastatic Disease. Cancer 118 : 2962-2970, 2012

4） Palma DA, et al : Stereotactic Ablative Radiotherapy versus Standard of Care Palliative Treatment in Patients with Oligometastatic Cancers （SABR-COMET） : A Randomised, Phase 2, Open-Label Trial. Lancet 393 : 2051-2058, 2019

5） Gomez DR, et al : Local Consolidative Therapy vs. Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer : Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol 37 : 1558-1565, 2019

6） Gillessen S, et al : Management of Patients with Advanced Prostate Cancer : Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol 77 : 508-547, 2020

7） Guckenberger M, et al : Characterisation and Classification of Oligometastatic Disease : A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer Consensus Recommendation. Lancet Oncology 21 : e18-e28, 2020

8） Yoshida S, et al : Classification of Oligometastatic Prostate Cancer with Additional Consideration for Hormone Sensitivity. World J Urol 40 : 871-873, 2022

9） Parker CC, et al : Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer （STAMPEDE）: A Randomised Controlled Phase 3 Trial. Lancet 392 : 2353-2366, 2018

10） Aizawa R, et al : Long-Term Clinical Outcomes of External Beam Radiation Therapy for Oligometastatic Prostate Cancer : A Combination of Prostate-Targeted Treatment and Metastasis-Directed Therapy. Int J Urol 28 : 749-755, 2021

11） Rogowski P, et al : Radiotherapy of Oligometastatic Prostate Cancer : A Systematic Review. Radiat Oncol 16 : 50, 2021

12） Battaglia A, et al : Novel Insights into the Management of Oligometastatic Prostate Cancer : A Comprehensive Review. Eur Urol Oncol 2 : 174-188, 2019

13） Ost P, et al : Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence : A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol 36 : 446-453, 2018

14） Phillips R, et al : Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer : The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 6 : 650-659, 2020

15） Deek MP, et al : Metastasis-Directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. Eur Urol Oncol 4 : 447-455, 2021

16） Nozaki K, et al : Carbon 11-Choline Positron Emission Tomography/Computed Tomography and Palliative Local Therapy for Castration-Resistant Prostate Cancer. Int Urol Nephrol 51 : 1763-1769, 2019

17） Yoshida S, et al : Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer : Localization of the Progressive Site as a Prognostic Factor. Int J Radiat Oncol Biol Phys 105 : 376-381, 2019

18） Yoshida S, et al : Genuine- and Induced-Oligometastatic Castration-Resistant Prostate Cancer : Clinical Features and Clinical Outcomes After Progressive Site-Directed Therapy. Int Urol Nephrol 53 : 1119-1125, 2021

19） Schick U, et al : Androgen Deprivation and High-Dose Radiotherapy for Oligometastatic Prostate Cancer Patients with Less Than Five Regional and/or Distant Metastases. Acta Oncol 52 : 1622-1628, 2013

20） Deek MP, et al : Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer : The Johns Hopkins Experience. Int J Radiat Oncol Biol Phys 105 : 948-956, 2019

21） Fodor A, et al : Toxicity and Efficacy of Salvage Carbon 11-Choline Positron Emission Tomography/Computed Tomography-Guided Radiation Therapy in Patients with Lymph Node Recurrence of Prostate Cancer. BJU Int 119 : 406-413, 2017

22） Ong WL, et al : Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography （PSMA-PET/CT） -Guided Stereotactic Ablative Body Radiotherapy for Oligometastatic Prostate Cancer : A Single-Institution Experience and Review of the Published Literature. BJU Int 124 （Suppl 1） : 19-30, 2019

F-Fluorocholine PET/CT Oligorecurrent Nodal Failures from Prostate Cancer. Eur J Nucl Med Mol Imaging 46 : 40-48, 2019

24） Kalinauskaite G, et al : 68Ga-PSMA-PET/CT-Based Radiosurgery and Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer. PLoS One 15 : e0240892, 2020

25） Decaestecker K, et al : Repeated Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence. Radiat Oncol 9 : 135, 2014

Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer. Int J Radiat Oncol Biol Phys 103 : 95-104, 2019

27） Pasqualetti F, et al : ［（18）F］ Choline PET/CT and Stereotactic Body Radiotherapy on Treatment Decision Making of Oligometastatic Prostate Cancer Patients : Preliminary Results. Radiat Oncol 11 : 9, 2016

28） Deek MP, et al : Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. Int J Radiat Oncol Biol Phys 109 : 387-395, 2021

29） Yoshida S, et al : Patterns of Failure After Progressive Site-Directed Therapy in Oligo-Progressive Castration-Resistant Prostate Cancer. Int J Urol 27 : 634-635, 2020

30） Lussier YA, et al : MicroRNA Expression Characterizes Oligometastasis （es）. PLoS One 6 : e28650, 2011